Kushner Joshua's Form 4 filing
Oscar Health, Inc. (OSCR) · filed Aug 27, 2021
- Accession no.
- 0000899243-21-034462
- Filed
- Aug 27, 2021
- Trade date
- Aug 25-27, 2021
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions. Open-market purchases total $6.29M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Kushner JoshuaCIK 0001844181 | Director, Officer (Co-Founder and Vice Chairman), 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 25, 2021 | Class A Common Stock | PPurchaseAcquired | +31,794 | $13.18F1 | +$419,044.92 | 1,300,578 | Indirect | |
| Aug 26, 2021 | Class A Common Stock | PPurchaseAcquired | +204,811 | $13.74F3 | +$2,814,103.14 | 1,505,389 | Indirect | |
| Aug 27, 2021 | Class A Common Stock | PPurchaseAcquired | +217,590 | $14.05F4 | +$3,057,139.5 | 1,722,979 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Represents (i) 31,415 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 379 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.09 to $13.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 1,285,094 shares are held directly by Thrive VII Growth and 15,484 shares are held directly by Claremount VII.
Referenced by the price of 1 transaction in Table I.
- F3
Represents (i) 202,373 shares purchased by Thrive VII Growth and (ii) 2,438 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.39 to $14.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 1,487,467 shares are held directly by Thrive VII Growth and 17,922 shares are held directly by Claremount VII.
Referenced by the price of 1 transaction in Table I.
- F4
Represents (i) 215,000 shares purchased by Thrive VII Growth and (ii) 2,590 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.72 to $14.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. 1,702,467 shares are held directly by Thrive VII Growth and 20,512 shares are held directly by Claremount VII.
Referenced by the price of 1 transaction in Table I.